Orion Bags Another Big Pharma Partner With Merck & Co Prostate Cancer Deal
Raises Outlook After Pact For ODM-208
Executive Summary
The Finnish group has concluded an extensive search to partner its first-in-class CYP11A1 inhibitor, banking an impressive $290m upfront fee for the Phase II drug which is being evaluated for metastatic castration-resistant prostate cancer.
You may also be interested in...
Orion Bemoans Bad Luck In Winner-Takes-All Biosimilar Tenders
Finland’s Orion is continuing to await the potentially uplifting effect of its biosimilar partnership with Aurobindo’s CuraTeQ Biologics, after another tricky year.
Merck Reports Good News/Bad News In Latest Keytruda Readouts
With successful Phase III data, Merck will look to add biliary tract cancer to Keytruda’s label, but it will discontinue a Phase III study in prostate cancer after an interim analysis showed no survival benefit.
Takeda Pays Big For De-Risked HutchMed CRC Drug
The Japanese pharma agreed to pay $400m up front plus up to $730m in milestones for a colorectal cancer drug already on the market in China and nearing regulatory filings in the US, EU and Japan.